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Treatment of pigs with endectocides 
as a complementary tool for combating malaria 
transmission by Anopheles farauti (s.s.) in Papua 
New Guinea
Cielo J. Pasay1*†, Laith Yakob2†, Hannah R. Meredith2, Romal Stewart1, Paul C. Mills3, Milou H. Dekkers4, 
Oselyne Ong5, Stacey Llewellyn1, R. Leon E. Hugo5, James S. McCarthy1† and Gregor J. Devine5*†
Abstract 
Background: Outdoor, early-biting, zoophagic behaviours by Anopheles farauti (s.s.) can compromise the effective-
ness of bed nets for malaria control. In the Western Pacific region, pigs and dogs represent significant alternative 
blood sources for mosquitoes. Treating these animals with endectocides may impact mosquito survival and comple-
ment control measures. This hypothesis was explored using membrane feeding assays (MFAs), direct feeds on treated 
pigs, pharmacokinetic analyses and a transmission model.
Results: Ivermectin was 375-fold more mosquitocidal than moxidectin (24 h  LC50 = 17.8 ng/ml vs 6.7 µg/ml) in MFAs, 
and reduced mosquito fecundity by > 50% at ≥ 5 ng/ml. Treatment of pigs with subcutaneous doses of 0.6 mg/kg 
ivermectin caused 100% mosquito mortality 8 days after administration. Lethal effects persisted for up to 15 days after 
administration (75% death within 10 days).
Conclusion: The application of these empirical data to a unique malaria transmission model that used a three-host 
system (humans, pigs and dogs) predicts that the application of ivermectin will cause a significant reduction in the 
entomological inoculation rate (EIR = 100 to 0.35). However, this is contingent on local malaria vectors sourcing a 
significant proportion of their blood meals from pigs. This provides significant insights on the benefits of deploying 
endectocides alongside long-lasting insecticide-treated nets (LLINs) to address residual malaria transmission.
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Background
The successful deployment of long-lasting insecticide-
treated nets (LLINs), indoor residual spraying (IRS), and 
effective anti-malarials has been responsible for highly 
significant declines in malaria prevalence around the 
globe. LLINs are crucial components of many malaria 
control successes [1], but, despite their mass distribu-
tion, transmission persists and is even resurging in some 
areas. In the Western Pacific, Papua New Guinea and the 
Solomon Islands account for 92% of the region’s malaria. 
Between 2010 and 2016, these countries respectively 
reported a > 400% and > 40% increase in cases [2].
One reason for the suboptimal effectiveness of LLINs 
is that they are only fully protective when humans are 
indoors and under their nets. In settings where malaria 
transmission is mediated by partially zoophagic vectors 
that exhibit early and outdoor biting behaviours, LLINs 
are less useful. One major vector that exhibits these traits 
is Anopheles farauti (s.s.) This species is responsible for 
much of the malaria transmission in Papua New Guinea, 
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the Solomon Islands and Vanuatu [3, 4]. It commonly 
feeds throughout the night, both indoors and outdoors, 
with a pronounced peak in activity in the early evening 
[5]. The propensity of An. farauti (s.s.) to feed on non-
human hosts is well-documented, and tends to increase 
in the presence of LLINs which, by protecting humans, 
serve to “push” mosquitoes to alternative hosts [6–8]. 
LLINs will continue to be a mainstay of malaria control 
in most malaria-endemic areas, but there is an urgent 
need for their deployment to be complemented by other 
vector control tools that help combat the behavioural 
resilience described above. One promising approach is 
to treat hosts with endectocides that kill mosquitoes that 
feed on those hosts [9–11].
Endectocides of interest include ivermectin and mox-
idectin, macrocyclic lactones that have a broad spectrum 
of activity against nematodes and arthropods, such as 
ticks, scabies mites and head lice [12]. The potential use 
of ivermectin-treated hosts to target mosquitoes was 
first recognized during the mass drug administration 
(MDA) of ivermectin to humans to combat filariasis [13, 
14]. This prompted a number of trials designed to exam-
ine impacts on Anopheles gambiae (s.l.) mortality when 
exposed to ivermectin-treated humans [15–17] and cattle 
[18–20]. More recently, the mosquitocidal effect of iver-
mectin against An. farauti was observed during an MDA 
strategy to control human scabies in the Solomon Islands 
[21].
Moxidectin is a highly lipophilic, second-generation 
macrocyclic lactone under development as an alterna-
tive to ivermectin for the treatment of onchocerciasis and 
human scabies [22, 23]. Although others have reported 
that moxidectin is far less toxic than ivermectin when 
presented to An. gambiae and An. arabiensis mosquitoes 
via membrane feeding assays or treated cattle [18, 24, 25], 
it is more potent than ivermectin against skin burrowing 
mites in pigs because of its accumulation in subcutane-
ous tissues [26]. As blood-feeding mosquitoes probe der-
mal blood vessels or extravasated blood just beneath the 
skin [27] it is possible that mosquitoes may be unusually 
exposed when feeding on live pigs.
The operational feasibility of mosquitocidal zoo-
prophylaxis is driven by the intrinsic host-preference of 
mosquitoes. Previous studies from Papua New Guinea 
(PNG) have reported that humans, pigs and dogs account 
for almost all blood meals taken by An. farauti (s.s.), and 
that the proportion of each blood resource taken depends 
on its relative abundance and availability [6, 8, 28, 29]. 
High LLIN coverage, making human hosts unavailable, 
appears to push vectors towards other hosts [6, 29]. Dogs 
are sometimes the preferred host of An. farauti and on 
occasion have been recorded to comprise > 40% of blood 
meals in PNG, despite their low abundance relative to 
human and pig populations [29]. For these reasons, we 
focused our empirical research and modelling on a hypo-
thetical malaria transmission system mediated by An. far-
auti (s.s.) utilising three main blood resources: humans, 
pigs and dogs.
Predicting the efficacy of an endectocidal zoopro-
phylactic treatment will rely on identifying the most 
pragmatic or effective route of drug administration, its 
pharmacokinetic properties in the target host and its 
pharmacodynamic effect on the target. Here, we inves-
tigated the impact of ivermectin and moxidectin on 
blood-feeding An. farauti (s.s.) using a combination of 
membrane feeding assays and direct feeds on treated 
pigs. Comparisons were made between drug levels in the 
blood resulting from subcutaneous (SC) injection, topical 
treatment, and oral treatment. Using the mortality data 
derived from the SC treatment, the effect of endectocide 
coverage and host choice was explored using an adapted 
transmission model [30, 31]. The model was used to sim-
ulate the impact of endectocidal treatments on both Plas-
modium falciparum and P. vivax malaria transmission 
for range of host preferences and endectocidal coverage. 
Projections were made for the transmission reductions 
that might be achieved and the potential to include the 
ivermectin treatment of domestic animals as part of an 
integrated vector management plan for malaria control.
Results
Membrane feeding assays (MFAs)
Results of MFAs showed a 375-fold difference in activity: 
24  h  LC50 of 17.8 ng/ml (95% CI: 13.6–22.7 ng/ml) and 
6700 ng/ml (95% CI: 5000–8700 ng/ml) for ivermectin 
and moxidectin respectively (Fig. 1). Below 3000 ng/ml, 
moxidectin had no impact on mosquitoes.
Further MFAs were undertaken to investigate the sub-
lethal effects of ivermectin on mosquito fecundity. Eggs 
laid by female mosquitoes that had fed on 5 and 10 ng/
ml ivermectin exhibited significantly decreased hatching 
rates (53.2% and 27.0%, respectively, P = 0.0053 (Fig.  2). 
The number of eggs laid was unaffected.
Pharmacokinetics and impact of live feeds
Pharmacokinetic assays on pigs treated with 0.6 mg/kg 
of drug by SC injection showed consistently higher lev-
els of ivermectin and moxidectin in the plasma compared 
with red blood cells or skin biopsies (Fig.  3, Additional 
file 1: Table S1). The maximum concentration  (Cmax) and 
half-life  (t1/2) of ivermectin in blood (plasma plus red 
blood cells) was 34.1 ng/ml and 4.0 days, respectively. 
The values for moxidectin were 83.7 ng/ml and 19.4 
days, respectively (Table  1). Ivermectin levels in treated 
pigs reflected the concentrations required to cause 24 h 
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mortality observed in vitro (MFAs) while moxidectin lev-
els did not.
In vivo, mosquitoes that fed on ivermectin-treated pigs 
(via SC injection) - 1, 3, 5 and 8 days post-treatment, 
died within 2–4 days. The mean plasma levels for these 
time points were 18.2, 32.8, 26.1, and 15.3 ng/ml iver-
mectin, respectively (Fig. 4). Fifteen days after treatment, 
the mean ivermectin plasma level had fallen below the 
24 h  LC50 (calculated from the MFA data) to just 2.4 ng/
ml, but mosquito survival remained significantly lower 
than controls at all time points 3–12 days after feeding 
(Fig.  4e). The effect of ivermectin treatment was insig-
nificant 22 days post-treatment of pigs (mean plasma 
level = 1.4 ng/ml). In comparison, the mean moxidectin 
plasma levels were always too low to affect mosquito 
survival.
The effects of ivermectin delivery were also compared. 
When 0.6 mg/kg was administered by oral or pour-on 
routes, blood levels were 66% and 97% lower in compari-
son to the levels observed after subcutaneous injection to 
pigs (Fig. 5, Table 1, Additional file 1: Table S2). Delivered 
orally, the mean blood level of ivermectin in pigs rose 
to19.9 ng/ml within 24 hours of treatment but declined 
to 6.2 ng/ml after 3 days and was not detectable after 7 
days. Pour-on delivery resulted in even lower blood levels 
(0.15–0.5 ng/ml).
No mosquito live feeds were performed on pigs treated 
via oral and pour-on routes, instead, we modelled a range 
of doses to determine the dose necessary to achieve a 
commensurate impact with SC injection. Results showed 
that equivalent bioavailability would be achieved at 
1.0–3.2 mg/kg via the oral route and 24.0–33.7 mg/kg 
via pour-on routes (Additional file  1: Table  S3). High 
variability in dose was observed between the three phar-
macokinetic parameters used for the equivalence calcula-
tions. As data were available for just two pigs for each of 
the oral, pour-on, and subcutaneous delivery methods, a 
larger sample size would be needed to make more confi-
dent estimates of the required doses.
Modelling outcomes
The impact of the strategy was estimated by calculating 
the relative entomological inoculation rate (EIR) from 
simulated populations of treated versus untreated popu-
lations of pigs and dogs. In the absence of any treatment, 
the annual EIR value was set to a conservative 100 infec-
tious bites per year. This reflects annual EIR estimates of 
100–1000 prior to LLIN roll-out in PNG [4].
The results shown in Fig.  6 are predicted reductions 
in EIR at the end of the 3-month period of treatment, 
relative to a no-control scenario. Malaria transmission 
could not continue  (R0 < 1) if fewer than 40% and 30% of 
blood-meals were taken from humans for P. falciparum 
and P. vivax, respectively. After 3 months of treatment, 
the P. falciparum and P. vivax models predicted signifi-
cant declines in EIR for a range of host-choice scenarios. 
Treating pigs alone, and, for example, assuming a human: 
pig: dog host choice ratio of 0.4: 0.4: 0.2 [6, 8] delivers a 
dramatic decrease in relative EIR (0.35).
Discussion
The endectocide ivermectin, when present in mamma-
lian blood and tissues, is widely recognised as having 
insecticidal activity against blood-feeding anopheline 
mosquitoes. Its short plasma half-life and operational 
challenges of mass administration to humans at effec-
tive doses [17] suggest that its mosquitocidal feasibility 
Fig. 1 In vitro activity of ivermectin and moxidectin 24 h 
post-membrane feeding. Lower concentrations of ivermectin than 
moxidectin are necessary to achieve the same mortality level in 
mosquitoes
Fig. 2 Effect of sublethal ivermectin concentration on mosquito 
fecundity. The proportion of hatched eggs decreased as the 
ivermectin concentration increased in the blood meal of mosquitoes
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in humans may be limited. Treatment of alternative 
hosts such as domesticated animals, using higher doses 
of ivermectin, with better residual activity, may offer 
more practicable means of implementation [32–34].
One potential target of such a strategy is An. farauti 
(s.s.), a partially zoophagic mosquito and a major vec-
tor of both P. falciparum and P. vivax in large parts of 
Papua New Guinea and the Western Pacific [35]. The 
first demonstration of ivermectin impacts on An. far-
auti (s.s.) was from a treated (0.250 mg/kg) human vol-
unteer. Blood-fed mosquitoes were affected up to 14 
days after drug administration [36]. That was the first 
paper to report on the potential impact of endectocidal 
zooprophylaxis in pigs. In this paper, we implemented 
an empirical and modelling study of that vector con-
trol strategy using a combination of membrane feed-
ing assays, live feeds on treated pigs, pharmacokinetic 
analysis and a transmission model.
Single subcutaneous injection of ivermectin in pigs 
caused serious impacts on An. farauti (s.s.) within two 
weeks of treatment. These outcomes would have pro-
found effects on vector populations, biting rates and 
entomological transmission parameters. Mosquitoes 
dying within 3 days will not survive the gonotrophic cycle 
[5] and are therefore reproductive dead ends. Mosquitoes 
dying within 10–12 days will not complete the sporo-
gonic cycle (extrinsic incubation period or EIP) of the 
parasite, and therefore will not transmit malaria. A com-
mon measure of the intensity of malaria transmission is 
the entomological inoculation rate (EIR). This estimates 
the number of infectious bites per person per unit time 
[37], and is usually calculated from measures of the num-
ber of bites per person per day and the fraction of those 
bites that are infectious (the “sporozoite rate”). Daily 
survival alone and in relation to EIP will have profound 
effects on those parameters and the EIR. Our research 
Fig. 3 Pharmacokinetic profiles for plasma, red blood cells, and skin. Ivermectin and moxidectin attained the highest concentrations in plasma and 
lowest in skin (n = 2 pigs per condition, dose = 0.6 mg/kg ivermectin or moxidectin)
Table 1 Summary of pharmacokinetic data in blood (plasma plus red blood cells) for pigs treated with 0.6 mg/kg of ivermectin or 
moxidectin
a Data are presented as a “Mean (Pig 1, Pig 2)”
b The moxidectin terminal half-life in blood may not be appropriate as the time interval the drug was measured over was not sufficient (< 2t1/2). Therefore, caution is 
required when interpreting the terminal half-life for moxidectin
Delivery method Ivermectin Moxidectin
Pour-ona Orala Subcutaneousa Subcutaneous
AUC 0-t (ng/ml∙d) 4.4 (3.4, 5.4) 48.3 (47.7, 52.8) 246.9 (218.3, 275.6) 686.7 (623.9–749.4)
AUC 0-∞ (ng/ml∙d) 5.9 (5.9, 5.9) 48.5 (43.9, 53.0) 256.6 (236.1, 277.0) 786.0 (745.0–827.0)
Cmax (ng/ml) 0.9 (0.5, 1.2) 19.9 (19.1, 20.7) 34.1 (26.4, 41.7) 83.7 (87.5–79.9)
Tmax (d) 3.0 (3.0, 3.0) 1.0 (1.0, 1.0) 2.0 (1.0, 3.0) 0.5 (0.5–0.5)
t1/2 (d) 6.1 (8.7, 3.4) 1.7 (1.8, 1.7) 4.0 (5.4, 2.6) 19.5 (21.5–17.4)
b
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has focused on An. farauti (s.s.) which is the major coastal 
vector throughout PNG [38]. In the presence of LLINs 
it is likely to be diverted to pigs; a characteristic which 
it shares with other established malaria vectors such as 
An. punctulatus [6]. Another partially zoophagic species, 
An. koliensis, may be a poorer target for the ivermectin 
treatment of domestic animals: the limited literature sug-
gests that humans are always this species’ favoured blood 
resource [6, 8] but that may make them more vulnerable 
to the impacts of LLINs.
Our results are similar to those reported for ivermec-
tin-treated cattle, and their impacts on An. gambiae 
(s.l.), despite the fact that pigs may exhibit lower  Cmax 
and AUC values for ivermectin as a result of increased 
sequestration in the fat tissues and more rapid decreases 
in plasma levels [39]. SC injection of cattle with 0.6 mg/
kg affected blood-feeding An. gambiae (s.l.) for two 
weeks after treatment (> 90% death within 10 days) [18], 
while subcutaneous injection with 0.2 mg/kg affected An. 
coluzzi for three weeks (> 75% death within 12 days) [20].
Membrane feeding assays performed in this study also 
suggest that blood concentrations of 5 ng/ml will reduce 
egg-hatch rates by > 50% in An. farauti. The impacts of 
ivermectin on the fecundity and fertility of Anopheles 
mosquitoes have been widely reported [18, 40] and may 
further reduce population density by affecting mosqui-
toes that survive the gonotrophic cycle and lay eggs. In 
focusing on the impacts of endectocide-associated mor-
tality on EIR, and not including impacts on fecundity, 
it is likely that the sizeable reductions in transmission 
achieved in our model simulations represent conserva-
tive estimates.
We had hypothesised that the ivermectin-related 
macrocyclic lactone moxidectin might be unexpectedly 
effective against An. farauti because of its pronounced 
lipophilicity, its remarkable efficacy on skin burrowing 
Fig. 4 Mosquito survival probability after direct feeding on ivermectin- and moxidectin-treated pigs. a–d At week one post-treatment of pigs (by 
SC injection of ivermectin and moxidectin), mosquitoes were allowed to feed on pigs on Day 1 (a), Day 3 (b), Day 5 (c) and Day 8 (d) post-treatment. 
Mean ivermectin plasma concentration detected in pigs on these feeding days was 18.2, 32.8, 26.1 and 15.3 ng/ml, respectively. Mosquito 
mortality after feeding was recorded and expressed as survival probability. Zero survival probability of mosquitoes was recorded within 2–4 days 
of feeding on ivermectin-treated pigs. Survival probability of mosquitoes that fed on moxidectin-treated pigs only increased at Day 1 (a) and 
Day 3 (b) post-treatment with mean drug plasma concentration of 50.5 and 40.2 ng/ml, respectively. Mosquitoes that fed on moxidectin-treated 
pigs were frozen and checked after Day 5 (a) and Day 10 (b) of monitoring to ensure presence of moxidectin (data not shown). From Day 5 and 
onwards (c–f), post-treatment of pigs with moxidectin, mean plasma concentrations of 37.4, 27.4, 14.2, 9.8 ng/ml, respectively, had no impact on 
mosquito survival. e At week two or Day 15 post-treatment of pigs, mosquito survival probability of 0 was observed on Day 12 after feeding on 
ivermectin-treated pigs with decreased mean plasma concentration of 2.4 ng/ml. f At week three or 22 days post-treatment of pigs, very low mean 
ivermectin plasma concentration of 1.45 ng/ml had no impact on mosquito survival. Survival probability was similar to mosquitoes that fed on 
moxidectin-treated pigs and untreated pigs (control)
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mites in pigs [26], and the fact that blood-feeding mos-
quitoes probe dermal blood vessels and extravasated 
blood just beneath the skin [27]. However, although mox-
idectin had a more favourable pharmacokinetic profile 
than ivermectin in pigs, it did not reach high concentra-
tions in the skin, and had no impact on mosquito mor-
tality. We therefore corroborate a report from cattle that 
shows no impact of moxidectin on An. gambiae at 0.6 
mg/kg [18].
Subcutaneous administration of ivermectin to animal 
herds using an injection gun is fast and simple (assum-
ing that animals can be adequately contained) but other 
routes of drug administration are of interest, particu-
larly for free-ranging or feral animals. We compared the 
pharmacokinetics of SC, topical and oral administration 
(0.6 mg/kg) and determined that topical application was 
the least efficient delivery method while oral treatment 
would require delivery at 1–3 mg/kg to achieve equiva-
lent levels of control. Although this is higher than the 
usual therapeutic dose of 0.3 mg/kg, it is well within the 
tolerable range for pigs (toxicity not observed until the 
dose exceeds 30 mg/kg [41].
Our model allowed for three hosts (humans, pigs and 
dogs) because they are the dominant resources that have 
been identified by the few studies conducted in Papua 
New Guinea that have conducted an unbiased blood 
meal survey [6, 8, 29]. Pig production is a traditional 
small-holder activity in PNG, with 50% of all rural house-
holds owning one or more pigs that graze or forage 
around the home [6, 42, 43]. Dogs are also very common 
in all villages with approximately one dog for every four 
humans [6]. The presence of LLINs and the availability of 
pigs and dogs can combine to reduce mosquito predation 
on humans and to increase the proportion of blood meals 
taken from alternative hosts [6, 29]. Pigs are the most 
important alternative host in terms of the proportion of 
blood meals taken by An. farauti (s.s.) but dogs can also 
contribute significantly (20–30% of blood meals) [6, 8]. 
Overall pigs and dogs can account for well over 50% of 
blood meals [6, 29].
Although the empirical data from this paper relate to 
the treatment of pigs, dogs are another potential resource 
to be treated. Following oral ivermectin administration 
(0.6 mg/kg) the  Cmax in dogs was consistently > 300 ng/
ml and plasma concentrations of >  5 ng/ml were noted 
until day 18 after treatment [44]. On that basis, we can 
assume that oral ivermectin treatment of dogs would be 
at least as effective as SC treatment of pigs.
The feasibility of treating animals with endectocides 
at fortnightly intervals in rural settings is untested, but 
it is possible that the practicability of the idea could be 
improved by involving members of the target commu-
nity [45] or the development of longer lasting ivermec-
tin formulations [33]. The application of ivermectin 
to domestic animals for malaria control also requires 
appraisal of a number of non-target issues. One attrac-
tive outcome of endectocidal zooprophylaxis may be 
the coincidental improvement of animal health through 
impacts on helminths, ticks and mites. In Pakistan, treat-
ment of cattle, sheep, and goats with topical pyrethroids 
reduced malaria incidence but also improved animal 
yields - thereby encouraging community participation in 
the programme [46]. A less desirable consequence might 
be the selection of drug resistance in helminths follow-
ing continual treatment. Although this is a particular risk 
in intensive livestock farming, selection pressures may be 
reduced in populations where there is no importation of 
resistant parasites, treatment is temporally or spatially 
limited and anthelminthic classes are rotated to reduce 
selection pressure. These measures can be so effective 
that, with careful management, ivermectin efficacy can 
be restored even in intensively farmed herds [47].
Conclusions
In this study, we investigated the impact of endec-
tocidal zooprophylaxis on An. farauti (s.s.) feeding 
on pigs. Anopheles farauti (s.s.) is the major vector 
of malaria across much of Papua New Guinea and 
has a partially exophilic, exophagic, early-biting and 
zoophagic behaviour. In this region, pigs and dogs 
Fig. 5 Blood concentrations of ivermectin in pigs delivered via 
subcutaneous injection, oral and pour-on routes. Subcutaneous 
injection of 0.6 mg/kg ivermectin in experimental pigs resulted in 
much higher mean blood levels of the drug (18.2, 32.8, 26.1 and 15.3 
ng/ml on week 1 and 2.4 ng/ml on week 2, (concentrations found 
lethal to mosquitoes) and longer residence time (up to 3 weeks) as 
compared to same drug concentration of 0.6 mg/kg delivered via 
oral and pour-on routes in experimental pigs. The mean lethal dose 
of 19.9 ng/ml delivered via oral route was detectable only after 24 h 
post-treatment of pigs and rapidly declined to 6.2 ng/ml after 3 days. 
This lethal dose was not reached by pour-on delivery
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contribute a high proportion of blood meals to that 
vector species. Our three-host model suggests that 
ivermectin treatment of those alternative hosts will 
have a profound effect on EIR and, therefore, on 
the transmission of both P. falciparum and P. vivax 
malaria. The approach will be complementary to 
LLIN use where those nets do not offer full protection 
against some vector behaviours and where they serve 
to “push” host-seeking mosquitoes to alternative hosts.
Methods
Study design
This study was conducted in two parts: in vitro studies 
at QIMR Berghofer, Brisbane, Queensland, and in vivo 
studies at the Queensland Animal Science Precinct 
(QASP), Gatton, Queensland, Australia.
Anopheles farauti mosquitoes
The An. farauti (s.s.) colony was derived from specimens 
collected in Rabaul, Papua New Guinea in 1972. Per-
mission to release this mosquito from quarantine was 
granted by the Australian Department of Agriculture 
Fisheries and Forestry in 2012. This made it suitable for 
feeding on treated pigs at the Gatton facility. The mos-
quito colony was maintained at QIMR Berghofer as pre-
viously described [48].
Preparation of drugs for membrane feeding assays
Ivermectin (Sigma-Aldrich 18898, St. Louis, MO, USA) 
or moxidectin (Sigma-Aldrich 33746, St. Louis, MO, 
USA) in powder form, were initially dissolved in DMSO 
to prepare stock concentrations of 10 mg/ml, and ali-
quots frozen at -20 °C. On the day of mosquito feeding, 
a frozen drug aliquot was thawed and diluted in PBS to 
Fig. 6 Impacts of endectocidal treatments on entomological inoculation rates (EIR) of P. falciparum (a-b) and P. vivax (c-d) following three months 
of fortnightly endectocidal (ivermectin) applications to pigs alone (a, c) or both pigs and dogs (b, d). Each point within the triangles refers to a 
relative EIR value that corresponds to a particular distribution of blood meals (human, pigs or dogs). In the absence of any control, annual EIR was 
set to equal 100 (Reimer, et al. [4]). Note the minimum proportion of human blood meals was 0.4 and 0.3 for P. falciparum and P. vivax to produce 
 R0 > 1. Within those limits, the relative EIR could be dramatically influenced by host choice. For example, in panel a, a mix of blood meal proportions 
from humans (0.4), treated pigs (0.4) and untreated dogs (0.2) results in a shift in relative EIR to 0.35
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the required concentrations. Each drug concentration for 
testing was added to anti coagulated blood (1 part drug: 
99 parts blood) collected from a human volunteer to 
reach a range of concentrations (ivermectin: 25–1000 ng/
ml; moxidectin: 600–100,000 ng/ml).
Phase I: Membrane feeding assays
Dose‑finding and mosquito mortality
Four- to 7-day-old female An. farauti mosquitoes were 
starved overnight prior to feeds. At least 20 mosqui-
toes were placed in gauze-sealed feeding cups. Feeding 
cups were prepared in triplicate per drug concentration 
and control. One ml of drug-spiked blood was delivered 
in glass feeders attached to a circulating water bath (37 
°C), and mosquitoes were allowed to feed on the blood 
through bovine caecum membranes for 30 min or until 
engorged. Afterwards, unfed mosquitoes were removed 
and blood-fed mosquitoes were maintained on 10% sugar 
solution in the QIMR Berghofer Insectary for 7 days 
while daily mortality was recorded.
Sublethal concentrations of ivermectin and mosquito 
fecundity
To investigate the effect of sublethal concentrations 
of ivermectin on An. farauti, human blood was spiked 
with sublethal concentrations of ivermectin (2.5, 5 and 
10 ng/ml) and female mosquitoes were allowed to feed 
through membranes for 30 min. Afterwards, unfed mos-
quitoes were removed from the cups and batches of fed 
mosquitoes were maintained on 10% sugar solution, 
transferred to cages with oviposition cups provided. 
Mosquitoes were monitored for 5 days after feeding and 
then removed from the cages. On day 10 the number of 
hatched eggs (larva) and total numbers of eggs in the ovi-
position cups were counted.
Phase II: Pharmacokinetics and live feeding
Treatment
Five 6-week-old pigs weighing 10–11 kg were ran-
domised to ivermectin (n = 2) and moxidectin (n = 2) 
treatment groups, with one pig serving as a no treatment 
control. Treated pigs were injected subcutaneously with 
either Ivermectin (Ivomec, Merial Ltd, Duluth, Georgia, 
USA) or Moxidectin (Cydectin, Virbac, Sydney,NSW, 
Australia) at 0.6 mg/kg body weight.
Blood draw and skin biopsy
Each pig was mildly sedated with 0.5–0.8 ml of Azaper-
one (Stresnil, Elanco, Greenfield, Indiana,USA) and laid 
on a cradle to facilitate blood sampling and conduct of 
direct mosquito feeds. At least 1 ml blood was extracted 
from all pigs at 0 hour (before treatment), 6 hours, 
and Days 1, 3, 5, 8, 15, 22 and 28 after treatment. After 
collection, plasma was separated from red blood cells and 
stored frozen. Skin punch biopsy (5 mm) was also per-
formed (under local anaesthetic) at the same time start-
ing from Day 1 onwards to Day 28. Blood draws and skin 
biopsies were continued for moxidectin-treated pigs up 
to Day 50 post-treatment. Blood and skin samples were 
sent to the Department of Chemical Pathology, Royal 
Brisbane Hospital, for pharmacokinetic analysis.
Pharmacokinetic analysis
Ivermectin and moxidectin levels were determined from 
plasma, red blood cells and skin biopsy samples collected 
from experimental pigs treated by subcutaneous injec-
tion at each sampling point by reverse phase isocratic 
ultra-performance liquid chromatography (UPLC) cou-
pled with fluorescence detection (Waters Corporation, 
Milford, MA, USA) following the manufacturer’s proto-
col. Briefly, blood samples (plasma and red blood cells) 
were deproteinised and extracted with 1 ml 100% metha-
nol. The samples were centrifuged after and the superna-
tant dried under air. Pig skin samples, were frozen and 
then microtomed to produce slices approximately one 
cell across. The frozen sections were then suspended in 1 
ml of 100% methanol and ultrasonicated for one hour. All 
analytes were then derivatised with N-methylimidazole 
and trifluoroacetic anhydride and 1 µl was injected onto 
the UPLC system. Internal standards: ivermectin (Sigma-
Aldrich, 18898, St. Louis, MO, USA) and moxidectin 
(Sigma-Aldrich 33746, St. Louis, MO, USA) in powder 
form were diluted with DMSO to prepare the calibration 
curve. Ivermectin and moxidectin were measured against 
a four-point calibration curve with drug levels expressed 
in ng/ml. Inter-run imprecision (% CV) across three lev-
els of Quality Control were <8%.
Ivermectin levels were determined from whole blood of 
treated pigs via oral and pour-on routes when drug deliv-
ery methods were investigated.
Mosquito feeding
Mosquito feeding was also performed at each sampling 
point starting from Day 1 post-treatment of pigs via SC 
injection. At least 20 female mosquitoes per cup (in trip-
licate cups) were starved overnight prior to direct feeding 
on experimental pigs. Mosquito cups were placed on the 
pig’s underbelly and allowed to feed for 15 min or until 
engorged. Mosquitoes were also allowed to feed on con-
trol pig that did not receive any treatment. After feed-
ing, unfed mosquitoes were removed from the cups and 
fed mosquitoes were maintained on 10% sugar solution 
at QIMR Berghofer Insectary, and mortality monitored 
daily for 12 days.
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Ivermectin via oral and pour-on routes of delivery
To investigate the pharmacokinetic profile following 
other methods of ivermectin administration to pigs, 
four experimental pigs were treated with the same dose 
(0.6 mg/kg) of ivermectin via oral route (Ivomec Liquid, 
Merial Ltd; n = 2 pigs) and via pour-on (Ivomec Pour-On, 
Merial Ltd; n = 2 pigs) and periodic blood draws (Day 1, 
3, 5, 8, 15, 22 and 28) were performed post-treatment 
to monitor blood levels. No mosquito live feeds were 
performed on pigs treated with ivermectin via oral and 
pour-on methods. Instead, required lethal doses to mos-
quitoes were calculated and described in the following 
statistical analysis.
Statistical analysis
Key pharmacokinetic (PK) parameters were determined 
using non-compartmental PK analysis using STATA/
MP Version 15.1 for plasma, red blood cells (RBC) and 
skin samples for each of the ivermectin and moxidectin-
treated pigs. Details of non-compartmental PK analysis 
methodology in plasma, RBC and skin are described in 
Additional file 1: Text S1.
Key PK parameters, AUC o-t, AUC o-inf, and  Cmax were 
used to determine the required equivalent dose of iver-
mectin administered to pigs using oral and pour-on 
delivery in comparison to subcutaneous injection, shown 
to have lethal effects to mosquitoes. Microsoft Excel was 
used to calculate relative ivermectin bioavailability (or 
the proportion reaching the blood) and dose required 
via oral and pour-on delivery to achieve similar effect on 
vector mosquitoes via subcutaneous injection. Details of 
drug bioavailability and dose required calculation meth-
odology are described in Additional file 1: Text S2.
Mosquito mortality resulting from MFAs was analysed 
using non-linear regression curve fit analysis in Graph 
Pad Prism v 7.00 (GraphPad Software, La Jolla California 
USA, www.graph pad.com) to calculate the  LC50 of each 
drug. Survminer (https ://cran.r-proje ct.org) was used to 
calculate probability of survival of mosquitoes that fed 
on treated pigs. Inkscape was used to plot all figures, in 
R statistical software package (http://www.R-proje ct.org).
Mathematical modelling
Predicting the efficacy of mosquitocidal zooprophylaxis 
strategies in a multiple host system is contingent on 
understanding the distribution of blood-meals amongst 
hosts and what drives mosquito host choice. It is notable 
that, in areas of high LLIN usage in some areas of Papua 
New Guinea, pigs may account for up to 50% of the blood 
resources for malaria transmitting mosquitoes such as 
An. farauti and An. punctulatus. This phenomenon is 
attributed to net use limiting the availability of human 
hosts. Dogs can also be a significant alternative host and 
may account for up to 20% of blood meals [6, 8]. To esti-
mate the potential impacts of ivermectin treatments, we 
used adapted transmission models of P. falciparum and P. 
vivax malaria [31] in which blood meals were taken from 
humans, pigs, and dogs. Both models made an assump-
tion that ivermectin was delivered fortnightly for three 
months to pigs alone or to both pigs and dogs.
A discrete time (1-day time step) compartmental model 
was constructed to describe the key processes underlying 
the transmission of P. falciparum and P. vivax. The model 
allows for vector bites to be distributed over three host 
types: humans (the only infection reservoir), pigs and 
dogs. This is in accordance with blood-meal analyses of 
vectors caught from malaria endemic regions of Papua 
New Guinea [6, 29]. Transmission dynamics were tracked 
according to the following set of equations:
whereby, humans are compartmentalised into 
‘S’usceptible, ‘E’xposed, ‘I’nfected and ‘L’atently infected; 
and vectors are susceptible (X), exposed (Y) or infec-
tious (Z). The difference equations track the proportions 
among the different compartments over time (in days), t. 
Model parameters, their assumed values and the litera-
ture from which the values were sourced are depicted in 
Table  2. This set of equations describes both P. falcipa-
rum and P. vivax transmission (setting the probability of 
hypnozoite formation, h, to zero simplifies the model to 
an SEIS formation that is standard for P. falciparum).
Additional mosquito mortality incurred through 
endectocidal application on pigs and dogs is denoted by 
 m2 and  m3, respectively. Following previously published 
methods [30, 31] efficacy of the endectocide was assumed 
to wane over time according to:  m2 = bite rate × propor-
tion of bites on pigs × coverage (assumed 100%) × maxi-
mum killing efficacy (100%) × [(1 − (ln(2)/8)t]. The term 
in the square brackets denotes the effective period over 
which treated pigs are lethal to mosquitoes (i.e. ~8 days). 
An equivalent waning function along with the same 
endectocidal half-life was assumed for treated dogs 
 (m3). The model does not consider sub-lethal impacts on 
mosquito fecundity, or the slower impacts on mosquito 
St+1 = 1− (Et + It + Lt)
Et+1 = Et + vphbZt(St + Lt)+ rLt − gEt
It+1 = It + gEt −
(
h+ f
)
It
Lt+1 = Lt + hIt − (vphbZt + r + c)Lt
Xt+1 = 1− (Yt + Zt)
Yt+1 = Yt + ItXtphbv − (d +m1 +m2 +m3)Yt
Zt+1 = Zt + dYt − (m1 +m2 +m3)Zt
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mortality that occur after feeding on pigs treated 15 days 
previously. Furthermore, this model assumes that the 
mosquito population is stable and density dependence at 
the larval stage will offset any decrease in population due 
to the endectocide’s reduction in fecundity. Hence, the 
model makes a conservative estimate of impact.
To determine the impact of mosquitocidal zooprophy-
laxis for different proportions of host availability, bites 
were randomly apportioned to humans, pigs, and dogs 
500 times. This generated an average annual entomologi-
cal inoculation rate (EIR) of ~100 under a P. falciparum 
scenario and ~50 under a P. vivax scenario.
Additional file
Additional file 1: Text S1. Non-compartmental pharmacokinetic data 
analysis for ivermectin and moxidectin treatment in pigs through plasma, 
red blood cells (RBC) and skin samples. Table S1. Summary of non-
compartmental PK data. Figure S1. Moxidectin concentration over time 
profile for the two pigs for each sample type. Figure S2. Natural Log of 
the moxidectin concentration over time profile for the two pigs for each 
sample type. Figure S3. Ivermectin concentration over time profile for the 
two pigs for each sample type. Figure S4. Natural log of the ivermectin 
concentration over time profile for the two pigs for each sample type. 
Text S2. The equivalent ivermectin dose determination for pour-on and 
oral administration to subcutaneous administration through comparisons 
of non-compartmental pharmacokinetic parameters. Table S2. Summary 
of Non-compartmental PK data for pigs treated with 0.6 mg/kg ivermec-
tin. Table S3. Oral and pour-on ivermectin doses required for equivalence 
to subcutaneous injection.
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